<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444167</url>
  </required_header>
  <id_info>
    <org_study_id>AK104-206</org_study_id>
    <nct_id>NCT04444167</nct_id>
  </id_info>
  <brief_title>A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>An Open-Label Multi-Center Phase Ib/II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 in Combination With Lenvatinib As the First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akeso Pharmaceuticals, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of
      anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for
      patients with advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, multi-cohort, open-label phase 1b/2 clinical study to evaluate the
      anti-tumor activity, safety, PK profile, immunogenicity and potential biomarkers of AK104
      plus lenvatinib for the treatment of advanced hepatocellular carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>the time of informed consent signed through 90 days after the last dose of AK104 and</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentrations of AK104</measure>
    <time_frame>From first dose of AK104 through 90 days after last dose of AK104</time_frame>
    <description>The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK104 through 90 days after last dose of AK104</time_frame>
    <description>The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>AK104 and Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight&lt;60kg,PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK104</intervention_name>
    <description>Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months</description>
    <arm_group_label>AK104 and Lenvatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months</description>
    <arm_group_label>AK104 and Lenvatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent form voluntarily.

          -  Histologically or cytologically documented hepatocellular carcinoma.

          -  BCLC stage C, and non-resectable BCLC stage B .

          -  At least one measurable lesion according to RECIST criteria.

          -  ECOG of 0 or 1.

          -  Adequate organ function.

          -  Estimated life expectancy of ≥3 months.

          -  For women of childbearing potential: agreement to remain abstinent; For men: agreement
             to remain abstinent.

        Exclusion Criteria:

          -  Histologically or cytologically documented fibrolamellar hepatocellular carcinoma,
             sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.

          -  History of hepatic encephalopathy or liver transplantation.

          -  Clinical significance of hydrothorax, ascites or pericardial effusion.

          -  Central nervous system metastases and/or carcinomatous meningitis.

          -  Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under
             thrombolytic therapy.

          -  Occurred arteriovenous thromboembolic events within 6 months before the first
             administration.

          -  Tumor volume &gt; 50% liver volume; portal vein tumor thrombus or inferior vena cava
             tumor thrombus.

          -  Inadequately controlled arterial hypertension.

          -  Attack of symptomatic congestive heart failure (LVEF&lt;50%); History of congenital long
             QT syndrome.

          -  Known presence or history of interstitial lung disease or required hormone treatment
             interstitial lung disease.

          -  Severe infections.

          -  Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy,

          -  Enrollment of another clinical study within 4 weeks prior to the first administration
             of study drugs.

          -  Unable to receive an enhanced CT or MRI scan of the liver.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Bai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shunchang Jiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weifeng Song, MD</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangfang Jing, MD</last_name>
    </contact>
    <investigator>
      <last_name>Li Bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shunchang Jiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 21, 2020</study_first_submitted>
  <study_first_submitted_qc>June 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VEGF</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Tyrosine Kinase Inhibitor (TKI)</keyword>
  <keyword>Anti-CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

